肝细胞腺瘤的分子分型在临床实践中的应用
肝细胞腺瘤(HCA)是年轻女性口服避孕药相关的罕见良性肝肿瘤,可并发出血或恶变为肝细胞癌。分子分型将HCA分为HNF1A失活型、炎症型、CTNNB1外显子3突变型、CTNNB1外显子7和8突变型、sonic hedgehog型及未分类型,其中CTNNB1外显子3突变型与高恶变风险相关、sonic hedgehog型与出血风险相关。本文综述分子分型如何改变对HCA发病机制和危险因素的理解,并分析其对诊断及治疗分层的影响。
要点
- 分子分型将HCA分为HNF1A失活型、炎症型、CTNNB1外显子3突变型、CTNNB1外显子7和8突变型、sonic hedgehog型及未分类型。
- CTNNB1外显子3突变型HCA与高恶变风险相关,sonic hedgehog型HCA与出血风险相关。
- 分子分型影响HCA诊断与治疗分层的临床管理。
核心结论
- 分子分型将HCA分为六个亚组,并与危险因素、临床行为、组织学特征和影像学表现相关联,CTNNB1外显子3突变型与高恶变风险相关、sonic hedgehog型与出血风险相关。
研究设计与样本
- 综述,分析分子分型对HCA发病机制、危险因素理解及诊断和治疗分层的影响。
主要发现
- 分子分型将HCA分为HNF1A失活型、炎症型、CTNNB1外显子3突变型、CTNNB1外显子7和8突变型、sonic hedgehog型及未分类型。
- CTNNB1外显子3突变型HCA与高恶变风险相关。
- sonic hedgehog型HCA与出血风险相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular adenomas (HCA) are rare benign liver tumors occurring in young women taking contraception. They are associated with rare complications such as bleeding or malignant transformation into hepatocellular carcinoma. A molecular classification has divided HCA in several subgroups linked with risk factors, clinical behaviour, histological features and imaging: HNF1A inactivated HCA, Inflammatory HCA, CTNNB1 mutated HCA in exon 3, CTNNB1 mutated in exon 7 and 8 HCA, sonic hedgehog HCA and unclassified HCA. CTNNB1 mutated HCA in exon 3 and sonic hedgehog HCA have been linked with a high risk of malignant transformation and bleeding respectively. Herein, we review how molecular classification has modified our understanding of the pathophysiology and risk factors of HCA development, analysing its impact on clinical care in the field of diagnosis and therapeutic stratification.
引用
- Nault JC, Paradis V, Cherqui D, et al. Molecular classification of hepatocellular adenoma in clinical practice. J Hepatol. 2017. PMID: 28733222. doi:10.1016/j.jhep.2017.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。